[go: up one dir, main page]

CY1115745T1 - Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου - Google Patents

Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου

Info

Publication number
CY1115745T1
CY1115745T1 CY20141100853T CY141100853T CY1115745T1 CY 1115745 T1 CY1115745 T1 CY 1115745T1 CY 20141100853 T CY20141100853 T CY 20141100853T CY 141100853 T CY141100853 T CY 141100853T CY 1115745 T1 CY1115745 T1 CY 1115745T1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
prevention
treatment
diseases
Prior art date
Application number
CY20141100853T
Other languages
English (en)
Inventor
Harmeet Sidhu
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35510266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115745(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of CY1115745T1 publication Critical patent/CY1115745T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση περιλαμβάνει μεθόδους και συνθέσεις για τη μείωση οξαλικών σε ανθρώπους, ζώα και φυτά. Για παράδειγμα, η εφεύρεση παρέχει μεθόδους και συνθέσεις για την παροχή ενός ή περισσότερων ενζύμων τα οποία μειώνουν τα οξαλικά στις εντερικές οδούς ατόμων και ζώων. Οι μέθοδοι και οι συνθέσεις μπορεί να χρησιμοποιηθούν σε αντιμετώπιση και πρόληψη σχετιζόμενων με οξαλικά παθήσεων.
CY20141100853T 2004-06-15 2014-10-16 Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου CY1115745T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/868,242 US8486389B2 (en) 1997-05-23 2004-06-15 Compositions and methods for treating or preventing oxalate-related disease
EP05786347.4A EP1771201B1 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease

Publications (1)

Publication Number Publication Date
CY1115745T1 true CY1115745T1 (el) 2017-01-25

Family

ID=35510266

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100853T CY1115745T1 (el) 2004-06-15 2014-10-16 Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY181101090T CY1120782T1 (el) 2004-06-15 2018-10-23 Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181101090T CY1120782T1 (el) 2004-06-15 2018-10-23 Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα

Country Status (13)

Country Link
US (3) US8486389B2 (el)
EP (2) EP1771201B1 (el)
CN (2) CN101166421A (el)
CY (2) CY1115745T1 (el)
DK (2) DK2803366T3 (el)
ES (2) ES2692148T3 (el)
HK (1) HK1216080A1 (el)
LT (1) LT2803366T (el)
PL (2) PL2803366T3 (el)
PT (2) PT2803366T (el)
SI (2) SI2803366T1 (el)
TR (1) TR201815200T4 (el)
WO (1) WO2005123116A2 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US20030113308A1 (en) * 2001-10-05 2003-06-19 Harmeet Sidhu Materials and methods for reducing oxalate concentrations in fluids
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20080317810A1 (en) * 2004-05-07 2008-12-25 Harmeet Sidhu Methods and Compositions for Reducing Oxalate Concentrations
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
WO2006130188A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
EP1928551B1 (en) 2005-06-10 2012-05-30 Althea Technologies, Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
PL1962873T3 (pl) * 2005-12-14 2014-03-31 Oxthera Intellectual Property Ab Kompozycje farmaceutyczne zawierające bakterie zmniejszające ilość szczawianu
WO2007075447A2 (en) * 2005-12-16 2007-07-05 Oxthera, Inc. Compositions and methods for oxalate reduction
AU2007347695A1 (en) 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
PL2449098T3 (pl) * 2009-07-02 2017-06-30 Oxthera Intellectual Property Ab Oczyszczanie i izolacja rekombinowanych enzymów rozkładających szczawian i cząstki suszone rozpryskowo zawierające enzymy rozkładające szczawian
DK2270138T3 (en) 2009-07-02 2018-06-25 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate-degrading enzymes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US9795657B2 (en) 2009-11-25 2017-10-24 Captozyme, Llc Methods and compositions for treating oxalate-related conditions
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
CA2913476A1 (en) 2013-06-07 2014-12-11 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
WO2015002588A1 (en) * 2013-07-05 2015-01-08 Oxthera Intellectual Property Ab Secretagogues derived from oxalobacter formigenes
KR20180044225A (ko) 2015-04-02 2018-05-02 캡토자임, 엘엘씨 불용성 및 가용성의 옥살레이트의 분해를 위한 고효율의 옥살레이트 분해 효소
CN109641019A (zh) * 2016-06-13 2019-04-16 奥克斯泰拉知识产权公司 用于治疗或预防草酸盐相关病症的组合物和方法
EP3554518A4 (en) 2016-12-15 2020-07-29 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR MODULATING THE GROWTH OF A GENETICALLY MODIFIED INTESTINAL BACTERIAL CELL
US12016899B2 (en) 2018-07-18 2024-06-25 The University Of Chicago Compositions comprising Sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
BR112021011221A2 (pt) 2018-12-10 2021-08-31 Novome Biotechnologies, Inc. Métodos e composições para tratar hiperoxalúria

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) * 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4888182A (en) 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) * 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5279827A (en) 1991-01-16 1994-01-18 Allegheny-Singer Research Institute Extract and pharmaceutical composition for treatment of calcium oxalate stone disease and viral infections
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
BR9307548A (pt) * 1992-11-30 1999-06-01 Zeneca Ltd Fragmento de dna isolado molécula recombinante célula de planta transformada oxalato decarboxilase composição processo para proteger uma planta de ácido oxálico e planta
WO1994023593A1 (en) * 1993-04-16 1994-10-27 Mccormick & Company, Inc. Encapsulation compositions
US5554147A (en) * 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
EP0764204B1 (en) 1994-05-18 2001-08-22 Human Genome Sciences, Inc. HUMAN OXALYL-CoA DECARBOXYLASE
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US6214980B1 (en) * 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US6033719A (en) * 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US20040120941A1 (en) 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
ES2334409T3 (es) 1997-05-23 2010-03-09 Oxthera, Inc., Microorganismos degradantes del oxalato o enzimas degradantes del oxalato para prevenir enfermedades relacionadas con el oxalato.
US6080404A (en) * 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) * 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
EP1119345B1 (en) 1998-10-09 2009-04-29 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
CN1365275A (zh) 1999-06-07 2002-08-21 南诺斯菲尔股份有限公司 包被颗粒的方法以及所得颗粒
DE10026541A1 (de) 2000-05-27 2001-11-29 Zeiss Carl Vorrichtung zur präzisen Positionierung eines Bauteils, insbesondere eines optischen Bauteiles
US20030113308A1 (en) * 2001-10-05 2003-06-19 Harmeet Sidhu Materials and methods for reducing oxalate concentrations in fluids
US7407668B2 (en) * 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
AU2003274918A1 (en) 2002-08-20 2004-03-11 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
US20080317810A1 (en) * 2004-05-07 2008-12-25 Harmeet Sidhu Methods and Compositions for Reducing Oxalate Concentrations
PL1962873T3 (pl) * 2005-12-14 2014-03-31 Oxthera Intellectual Property Ab Kompozycje farmaceutyczne zawierające bakterie zmniejszające ilość szczawianu
WO2007075447A2 (en) 2005-12-16 2007-07-05 Oxthera, Inc. Compositions and methods for oxalate reduction
AU2007347695A1 (en) 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
EP2803366A2 (en) 2014-11-19
EP2803366A3 (en) 2015-02-18
US20140030324A1 (en) 2014-01-30
PL2803366T3 (pl) 2018-12-31
EP1771201A2 (en) 2007-04-11
PT1771201E (pt) 2014-11-06
TR201815200T4 (tr) 2018-11-21
CN104998253A (zh) 2015-10-28
WO2005123116A3 (en) 2008-01-03
EP1771201A4 (en) 2011-01-19
HK1198922A1 (en) 2015-06-19
HK1216080A1 (zh) 2016-10-14
CN101166421A (zh) 2008-04-23
SI2803366T1 (sl) 2018-12-31
EP2803366B1 (en) 2018-08-01
EP1771201B1 (en) 2014-08-13
PL1771201T3 (pl) 2015-01-30
WO2005123116A2 (en) 2005-12-29
ES2522898T3 (es) 2014-11-19
US10653726B2 (en) 2020-05-19
US20040234514A1 (en) 2004-11-25
SI1771201T1 (sl) 2014-12-31
LT2803366T (lt) 2018-12-27
DK1771201T3 (da) 2014-11-03
US8486389B2 (en) 2013-07-16
DK2803366T3 (en) 2018-11-05
US10149866B2 (en) 2018-12-11
PT2803366T (pt) 2018-11-06
CY1120782T1 (el) 2019-12-11
ES2692148T3 (es) 2018-11-30
US20190091268A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1109240T1 (el) Συνδυασμος που περιλαμβανει βαλσαρτανη, αμλοδιπινη και υδροχλωροθειαζιδιο
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
CY1116093T1 (el) Χρηση νιντεντανιμπης για την αγωγη της πνευμονικης ινωσεως
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
EA200701918A1 (ru) Белок липокалин
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1110954T1 (el) Ημιστερεες βλεννοκολλωδεις φαρμακοτεχνικες μορφες
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
DE602004024037D1 (de) Substituierte heterozyklen